Skip to content

Treatment Action Group Statement on Early Findings from HPTN 084

  • Dorrit Walsh
Treatment Action Group welcomes the announcement that the phase 3 HPTN 084 trial proved that intramuscular injections of ViiV’s long acting cabotegravir (CAB-LA) every eight weeks were superior to daily oral TDF/FTC pre-exposure prophylaxis (PrEP) in preventing new HIV infections in cisgender women in sub-Saharan Africa.
Read more

Letter to Special Rapporteur on Cultural Rights

  • Dorrit Walsh
Our current letter follows an earlier letter dated June 23, 2020 and calls on the Special Rapporteur for cultural rights to explicitly acknowledge the human rights dimensions of science and reaffirm the right of everyone to participate in and enjoy the benefits of scientific progress and its applications in her forthcoming communication with the United Nations General Assembly on COVID-19.
Read more
Cover image of A Landscape Analysis of HIV Cure-Related Clinical Research in 2019–Community Survey

A Landscape Analysis of HIV Cure-Related Clinical Research in 2019

  • Dorrit Walsh
In 2018, the Bill & Melinda Gates Foundation contracted TAG to undertake a survey of investigators conducting studies included in our “Research Toward a Cure” clinical trials listing. TAG conducted this second survey in the fall of 2019 to track any changes over time and provide updated information on status of the field.
Read more

Treatment Action Group Condemns Reported Bullying, Harassment, and Racism at Stop TB Partnership

  • Dorrit Walsh
Treatment Action Group (TAG) strongly condemns alleged bullying, harassment, and racism directed toward staff and contractors of the Stop TB Partnership, as reported by The New York Times. As a long-term and current grantee of the Stop TB Partnership, we stand in solidarity with current and former staff and contractors whom this harassment and racism has affected.
Read more
Back To Top